Lifestyle-related factors and environmental agents causing cancer: An overviewGemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.Preliminary results of phase I and II clinical trials of RFCNU, a new nitrosourea sugar derivative, in digestive tract tumours.Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypesReliable disease biomarkers characterizing and identifying electrohypersensitivity and multiple chemical sensitivity as two etiopathogenic aspects of a unique pathological disorder.The multitude and diversity of environmental carcinogens.Environment as a potential key determinant of the continued increase of prostate cancer incidence in martinique.Increase in "Null" cells in acute lymphocytic leukaemia in remission on long-term immunotherapyReplicative random mutations as an unproven cause of cancer: A technical comment.The growing incidence of cancer: role of lifestyle and screening detection (Review).Overweight/obesity and cancer genesis: more than a biological link.Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis.Why pesticides could be a common cause of prostate and breast cancers in the French Caribbean Island, Martinique. An overview on key mechanisms of pesticide-induced cancer.Basic properties and molecular mechanisms of exogenous chemical carcinogens.Letter: T and B lymphocytes in spleen in Hodgkin's disease.Letter: Remission induction in acute lymphoid and acute myeloid leukaemias.Clinical significance and prognostic value of the T-B immunological classification of human primary acute lymphoid leukaemias.mu-chain disease. Report of two new cases.[Results of 3 protocols of treatment of acute lymphoid leukemia in children]Preliminary results of three protocols for the treatment of acute lymphoid leukaemia of children: distinction of two groups of patients according to predictable prognosis.[Leukaemias and lymphomas treatment by vindesine. Result of a phase II trial in terms of remission induction (author's transl)]Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.T and B lymphocytes and monocytes in the spleen in Hodgkin's disease: the increase in T lymphocytes in involved spleens.Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Etiological, clinical and prognostic significance of the T-B immunological classification of primary acute lymphoid leukemias and non Hodgkin's lymphomas.An immunological classification of leukemias and non Hodgkin's hematosarcomas based on T and B cell membrane markers with special reference to null "cell" disorders.Combination chemotherapy with adriamycine, VM 26, cyclophosphamide and prednisone in lymphosarcoma and reticulosarcoma stage III and IV.Are circulating null cells in patients submitted to long-term immunotherapy, related to K cells?Clinical trial of poly I--poly C as an immunity adjuvant and an immunorestoration agent.Advanced ovarian cancer. Carboplatin versus cisplatin.Advanced epithelial ovarian cancer: 1993 consensus statements.Results in children of acute lymphoid leukemia: protocol ICIG-ALL 9 consisting of chemotherapy for only 9 months followed by active immunotherapy: comparison with the results of more prolonged chemotherapy protocols. Recognition of two groups of acuCategorization of non-Hodgkin's hematosarcomas (lymphomas) according to T- and B-cell markers: its value for diagnosis and prognosis.Comparison between membrane markers and enzyme markers in 26 cases of non-Hodgkin's malignant lymphomas.T and B spleen lymphocytes in Hodgkin's disease.Critical study of the mononuclear leukocyte morphology based on scanning electron microscopy in normal subjects and in patients with lymphoid or monocytoid proliferative disorders. Comparison with the T, B or null cell membrane phenotypes.[Response of bone metastases to medical treatment: definition of evaluation criteria and classification trials]Selective induction of apoptosis in myeloid leukemic cell lines by monoacetone glucose-3 butyrate.Butyric acid and its monosaccharide ester induce apoptosis in the HL-60 cell line.
P50
Q22252510-cf837e97-491c-c9b7-fa01-c552ec72f3d9Q33357068-8D0DEB52-FCEA-4A37-AB79-22CFF5148AD5Q33451344-48AFB4BB-D4BD-4AAA-8EF2-7373E7F8C6D0Q34221728-A03717F2-A0D0-46A7-9E36-9F2D8C779DD9Q34503321-E2F00CD1-40CB-4FAD-AD42-9B2793E4C75FQ34661971-9e63fae2-4f13-2470-65f6-a9404861d97bQ35608923-A16EC566-5450-4372-8CDC-91317833EC70Q36068365-1853373E-B42D-4761-A83D-6D0915953B8FQ36741125-30A8DE13-8250-4B6B-BF5F-124931052F76Q36772410-0c5b4f86-4862-13aa-c400-80ce0a0929d1Q37012721-10FB88EC-8DE5-4D36-8CDA-63E9401C2BF5Q37368367-D3900F0A-48A9-4F21-8927-ED8E888FE00EQ37537842-61C21212-EF62-4E89-811E-784B6F028540Q37621779-DDCE5157-90B1-4924-B0C7-FB45AF0A1D66Q39321503-DB2A32A7-7728-4278-B0FE-0FD9C4E6F1BAQ39378130-EAA31B77-F205-48D7-A715-D5E730F2E80EQ39424346-1B41222D-56DC-4413-AECC-0A64511DCADCQ39664140-AC150158-C91F-408F-B639-64A4CF7AB8A0Q40510992-256687D5-2BBA-4BA1-A222-6993585BCABDQ40518993-3A768D12-5298-46A3-8C0F-4E2A564C1FA8Q40526743-37CDDC67-3A56-431D-8867-44346C61BBEEQ40532510-9B77DE6A-3AC8-4D3F-A142-3102C871D1B9Q40599854-1574856E-9A35-4E2A-80A9-BDB19A059FF0Q40649480-B2302A2B-259E-4D71-968E-3451E2B04F4DQ40666961-03F33863-B50E-4885-9723-CC6AFE0C1607Q40671382-E551A06D-2CF1-42F9-8021-108966AD4063Q40780350-F3BC38CB-D09E-46F3-B5A1-8F16EFB965BFQ40780375-6B62D8DB-6EEF-4FA7-9044-8FEF754BA590Q40780390-9143D482-AE4D-45F0-ADF1-315768FE6647Q40780399-AF798A3D-D65B-4F7E-9036-D1F537E71B55Q40816392-F8E5B15A-3EA2-485E-9990-68B848545AC3Q40816415-0DBCAC5E-1158-420E-B29A-5D26D1CB662BQ40852340-42D0E641-25E2-4CCE-AAAD-4298C9F55928Q40984795-C2A62A57-30B0-4878-B571-A9C859068391Q40984823-8E158BE1-F646-4014-9BD3-C914A7415398Q41249527-0B7EAFED-4B21-4672-B1E9-9B3787E8FBBEQ41291072-B1ACCFF4-A0A2-4F8E-BF90-9D483EA48A9BQ41313259-FC599B04-257C-408E-BF08-C2AE4CB65995Q41466739-52D4A289-8249-44A8-9060-53CD69C1E065Q41533006-9E64F3DB-9374-4AC4-94BE-537042D492D4
P50
description
Frans arts
@nl
French physician
@en
French physician
@en-ca
French physician
@en-gb
Prantsusmaa arst
@et
dochtúir Francach
@ga
dokter asal Perancis
@id
fransk lege
@nb
medic francez
@ro
medico francese
@it
name
Dominique Belpomme
@ast
Dominique Belpomme
@ca
Dominique Belpomme
@da
Dominique Belpomme
@de
Dominique Belpomme
@en
Dominique Belpomme
@es
Dominique Belpomme
@fr
Dominique Belpomme
@hu
Dominique Belpomme
@it
Dominique Belpomme
@nb
type
label
Dominique Belpomme
@ast
Dominique Belpomme
@ca
Dominique Belpomme
@da
Dominique Belpomme
@de
Dominique Belpomme
@en
Dominique Belpomme
@es
Dominique Belpomme
@fr
Dominique Belpomme
@hu
Dominique Belpomme
@it
Dominique Belpomme
@nb
prefLabel
Dominique Belpomme
@ast
Dominique Belpomme
@ca
Dominique Belpomme
@da
Dominique Belpomme
@de
Dominique Belpomme
@en
Dominique Belpomme
@es
Dominique Belpomme
@fr
Dominique Belpomme
@hu
Dominique Belpomme
@it
Dominique Belpomme
@nb
P1416
P214
P244
P268
P269
P106
P1412
P1416
P1559
Dominique Belpomme
@fr
P19
P21
P213
0000 0003 7826 6725
P214
P244
n2004010632
P268
P269
P27
P31
P3630
P4124
dominique-belpomme_27831
P496
0000-0002-9132-2077
P569
1943-03-14T00:00:00Z
P735
P7859
lccn-n2004010632